Daniel G Tenen Selected Research

Gefitinib (Iressa)

7/2010	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
11/2008	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
7/2008	Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
3/2008	Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
11/2007	Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
10/2007	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
10/2007	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
8/2005	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
8/2005	An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
2/2005	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel G Tenen Research Topics

Disease

48	Neoplasms (Cancer) 10/2022 - 01/2002
41	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 01/2002
34	Leukemia 10/2021 - 02/2003
18	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2002
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 01/2005
7	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2021 - 11/2003
6	Hepatocellular Carcinoma (Hepatoma) 12/2019 - 09/2011
6	Myeloid Leukemia (Leukemia, Myelocytic) 01/2019 - 01/2003
4	Acute Promyelocytic Leukemia 08/2015 - 11/2003
4	Genetic Translocation (Chromosomal Translocation) 09/2014 - 02/2003
3	Adenocarcinoma 01/2021 - 07/2010
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 06/2006
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019 - 12/2017
3	Carcinogenesis 07/2008 - 02/2006
2	Liver Neoplasms (Liver Cancer) 01/2021 - 09/2011
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 12/2017
2	Breast Neoplasms (Breast Cancer) 01/2017 - 07/2010
2	Blast Crisis (Blast Phase) 09/2015 - 05/2006
2	Hematologic Neoplasms (Hematological Malignancy) 10/2014 - 02/2009
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Hematologic Diseases (Blood Diseases) 10/2021
1	Dementia (Dementias) 01/2021
1	Cognitive Dysfunction 01/2021
1	Critical Illness (Critically Ill) 10/2020
1	COVID-19 10/2020
1	Neoplasm Metastasis (Metastasis) 01/2020

Drug/Important Bio-Agent (IBA)

37	Transcription Factors (Transcription Factor)IBA 10/2021 - 01/2002
27	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2002
23	CCAAT-Enhancer-Binding Protein-alphaIBA 12/2010 - 01/2002
13	ErbB Receptors (EGF Receptor)IBA 01/2018 - 01/2005
11	Tyrosine Kinase InhibitorsIBA 12/2021 - 08/2005
11	Gefitinib (Iressa)FDA Link 07/2010 - 01/2005
9	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2013
9	CCAAT-Enhancer-Binding ProteinsIBA 01/2019 - 02/2003
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2010 - 08/2005
6	MicroRNAs (MicroRNA)IBA 12/2021 - 09/2011
6	ChromatinIBA 10/2021 - 10/2014
6	proto-oncogene protein Spi-1IBA 08/2008 - 01/2003
4	Pharmaceutical PreparationsIBA 01/2020 - 04/2010
4	Peptides (Polypeptides)IBA 01/2018 - 10/2007
4	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 02/2008 - 02/2003
4	Retinoic Acid Receptor alphaIBA 10/2006 - 02/2003
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2003
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 08/2015 - 11/2003
3	ElementsIBA 03/2011 - 01/2006
2	entinostat (MS 275)IBA 12/2021 - 11/2016
2	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 03/2014
2	Histones (Histone)IBA 01/2021 - 01/2017
2	T-Cell Acute Lymphocytic Leukemia Protein 1IBA 01/2019 - 12/2017
2	Long Noncoding RNAIBA 01/2019 - 10/2018
2	EnzymesIBA 11/2018 - 07/2008
2	coactivator-associated arginine methyltransferase 1IBA 11/2018 - 07/2010
2	Adenosine (Adenocard)FDA LinkGeneric 01/2018 - 05/2014
2	Histone Deacetylase InhibitorsIBA 11/2016 - 04/2014
2	CytokinesIBA 05/2015 - 07/2006
2	Biomarkers (Surrogate Marker)IBA 10/2013 - 09/2011
2	TensinsIBA 06/2013 - 02/2013
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 06/2013 - 02/2013
2	Serine (L-Serine)FDA Link 02/2013 - 11/2006
2	Phosphotransferases (Kinase)IBA 07/2008 - 02/2006
2	Hepatocyte Nuclear Factor 3-betaIBA 07/2008 - 06/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2006 - 08/2005
2	CCAAT-Enhancer-Binding Protein-betaIBA 07/2006 - 11/2003
2	anilinoquinazolineIBA 08/2005 - 02/2005
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	Lysine (L-Lysine)FDA Link 01/2021
1	CalciumIBA 01/2021
1	Cell Adhesion MoleculesIBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	Neutralizing AntibodiesIBA 10/2020
1	Immunoglobulin G (IgG)IBA 10/2020
1	HemopexinIBA 01/2020
1	Heme (Haem)IBA 01/2020
1	Excipients (Suspending Agents)IBA 01/2020
1	Deubiquitinating EnzymesIBA 01/2020
1	Sorafenib (BAY 43-9006)FDA Link 12/2019
1	OligomycinsIBA 12/2019
1	Adenosine Triphosphate (ATP)IBA 12/2019
1	Enhancer RNAsIBA 01/2019
1	Atorvastatin (Lipitor)FDA Link 01/2019
1	Untranslated RNA (Noncoding RNA)IBA 01/2019
1	Small Cytoplasmic RNAIBA 01/2019
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019
1	CholesterolIBA 01/2019
1	MethyltransferasesIBA 11/2018
1	Arginine (L-Arginine)FDA Link 11/2018
1	QuinazolinonesIBA 08/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	immune RNA (I-RNA)IBA 01/2018
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 01/2018
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2018
1	Basic Helix-Loop-Helix Transcription FactorsIBA 01/2018
1	Nucleosomes (Nucleosome)IBA 01/2018

Therapy/Procedure

13	Therapeutics 12/2021 - 08/2002
2	Aftercare (After-Treatment) 01/2022 - 10/2020
2	Transplantation 10/2014 - 08/2012
1	Hematopoietic Stem Cell Transplantation 10/2021
1	Immunotherapy 01/2021
1	Radiotherapy 01/2020
1	Injections 12/2019